What is the primary objective of this study?

The XEN1101 Phase 1 clinical trial is a randomized, double-blind, placebo-controlled study that will eventuate the safety, tolerability, pharmacokinetics (PK) and effects on transcranial magnetic stimulation (TMS) of oral doses of XEN1101 in healthy male subjects.The TMS procedure is designed to demonstrate delivery of XEN1101 into the central nervous system and to observe a change in cortical excitability as measured by EEG and/or EMG activity. It is estimated there will be approximately 15 subjects in the planned study.

Who is eligible to participate?

Key Inclusion Criteria: - Healthy male aged between 18 and 55 years inclusive with a body mass index (BMI) between 18.5 and 30.0 kg/m2 - Right-handed only - Must agree to use effective methods of contraception, if applicable - Able to swallow multiple capsules - Able to provide written, personally signed and dated Informed Consent Form Key Exclusion Criteria: - Any current and relevant history of significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk, affect clinical or laboratory results, or the subject's ability to participate in the study - Any clinically significant abnormalities in vital signs, ECGs, physical examinations, or laboratory evaluations - Answering \"yes\" to any of the questions within the Columbia Suicide Severity Rating Scale Mental incapacity or language barriers precluding adequate understanding, cooperation, and compliance with the study - No prescription or over-the-counter (OTC) medications (including multivitamins, herbal or homeopathic preparations 14 days or if applicable/available, 5 half-lives prior to dosing to study end - Any history of severe head trauma - No smoking 60 days prior to dosing to study end

Which medical condition, disease, disorder, syndrome, illness, or injury is researched?

Healthy Male Volunteers

Study Interventions

Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.

Drug:XPF-008Capsule filled with XEN1101

Drug:Microcrystalline CellulosePlacebo capsule

Study Arms

Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.

XPF-008Single oral dose

PlaceboSingle oral dose

Study Status

Recruiting

Start Date: February 13, 2018

Completed Date: July 2018

Phase: Phase 1

Type: Interventional

Design:

Primary Outcome: Number of participants with adverse events (AEs) as assessed by CTCAE v4.03

Secondary Outcome: Maximum Observed Plasma Concentration (Cmax)

Study sponsors, principal investigator, and references

Principal Investigator: Gregory Beatch, PhD

Lead Sponsor: Xenon Pharmaceuticals Inc.

Collaborator:

More information:https://clinicaltrials.gov/show/NCT03468725